Karim Fizazi

22PUBLICATIONS
247CO-AUTHORS
Molecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|May 07, 2026
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Nov 11, 2025
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Alicia K Morgans, Alex Chehrazi-Raffle, Tamim Niazi

|Aug 07, 2025
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.

Mihaela Aldea, Emeline Orillard, Alice Bernard-Tessier

|Mar 05, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara

|Aug 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.

Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon

Pageof 4